Zymeworks CEO Kenneth Galbraith and Daiichi Sankyo CEO Sunao Manabe
Daiichi and Zymeworks end antibody pact after seven years
Zymeworks and Daiichi Sankyo ended a seven-year collaboration on bispecific antibodies last week.
Under the 2016 agreement, Zymeworks licensed its Azymetric and Efect platforms to Daiichi Sankyo to develop one bispecific antibody therapy in exchange for technology access fees and milestone payments and royalties, according to SEC filings. But Zymeworks also got something else in return, in the form of licenses to certain immuno-oncology antibodies from Daiichi.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters